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Abstract
The most recent genome-wide association study of migraine increased the total number of known migraine risk loci to 38. Still,
most of the heritability of migraine remains unexplained, and it has been suggested that rare gene dysregulatory variants play an
important role in migraine etiology. Addressing the missing heritability of migraine, we aim to fine-map signals from the known
migraine risk loci to regulatory mechanisms and associate these to downstream genic targets. We analyzed a large cohort of
whole-genome sequenced patients from extended migraine pedigrees (1040 individuals from 155 families). We test for associ-
ation between rare variants segregating in regulatory regions with migraine. The findings were replicated in an independent case-
control cohort (2027 migraineurs, 1650 controls). We report an increased burden of rare variants in one CpG island and three
polycomb group response elements near four migraine risk loci. We found that the association is independent of the common risk
variants in the loci. The regulatory regions are suggested to affect different genes than those originally tagged by the index SNPs
of the migraine loci. Families with familial clustering of migraine have an increased burden of rare variants in regulatory regions
near known migraine risk loci, with effects that are independent of the variants in the loci. The possible regulatory targets suggest
different genes than those originally tagged by the index SNPs of the migraine loci.
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Introduction
Migraine is a debilitating and complex genetic disorder with 1
billion affected individuals worldwide and a life-time preva-
lence of 15–20% [1]. Given the high prevalence, migraine has
a considerable social and economic impact, with annual ex-
penses estimated at €27 billion in Europe alone [2].
Furthermore, the Global Burden of Disease Study (2016)
ranks migraine the second highest cause of disability world-
wide [3]. Migraine is characterized by episodes of moderate to
severe throbbing, unilateral headache, which intensifies with
an increase in physical activity, and is accompanied by nausea
and increased sensitivity to light and sound [4]. Rare variants
with large effect sizes may be implicated with a high migraine
risk [5]. The most recent meta-analysis on migraine genome-
wide association studies (GWAS) identified 44 independent
SNPs defining 38 migraine risk loci [6]. However, a GWAS
typically assesses common SNPs derived from imputation and
genotyping, and thus effect sizes are small. Using next gener-
ation sequencing, it is possible to assess rare variants. Such
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rare variants are expected to have a larger effect size, particu-
larly if the variant segregates with disease within families [7].
Common complex disorders, such as migraine, are thought to
be influenced by alterations in gene regulation [8, 9]. As mi-
graine symptoms occur episodically and can be affected by
regulatory factors, such as hormones [10, 11], it is very likely
that gene dysregulation plays an important role in migraine
etiology. SNPs that affect gene regulation or are present in
regulatory regions have been linked with migraine [12, 13],
which further supports the impact of regulatory dysfunction
on the disorder. However, most of these SNPs are common
with small effect sizes and fail to explain a high migraine risk.
We assessed whether rare variants in regulatory regions in
known migraine risk loci have an increased risk burden for
migraine. Additionally, we investigated whether the rare reg-
ulatory variants had effects that are independent of the variants
in the migraine risk loci. We employed a cohort of extended
families with familial clustering of migraine and performed
whole-genome sequencing to identify rare variants. The find-
ings were replicated in an independent case-control cohort of
sporadic migraineurs with no familial history of migraine and
controls.
Materials and methods
Familial cohort
A total of 155 families with familial clustering of migraine
were recruited. The families consisted of 1040 subjects (mean
number of individuals per family = 6.7) of which 746 individ-
uals were diagnosed with migraine (mean number of
migraineurs per family = 4.8) and 294 had no history of mi-
graine. The smallest families consisted of at least two individ-
uals and at least one migraineur. A proband from each family
was initially recruited at the Danish Headache Center,
Rigshospitalet-Glostrup, Denmark, and the remaining family
members were subsequently recruited, as described elsewhere
[14]. All subjects were assessed by a neurologist or a senior
medical student trained in headache diagnostics using a vali-
dated semi-structured interview [15, 16] based on the
International Classification of Headache Disorders [4].
Replication cohort
The replication cohort consisted of 2027 sporadic migraineurs
(no first-degree relatives with migraine) and 1650 controls.
The sporadic migraineurs were recruited and interviewed at
the Danish Headache Center using the same procedures as
described for the probands of the familial cohort. The controls
were recruited for the Danish study of Non-Invasive testing in
Coronary Artery Disease (Dan-NICAD) according to proce-
dures described by Nissen et al. [17].
Sequencing
Genomic DNAwas extracted from whole blood. All samples
from both the familial cohort and the replication cohort were
subjected to the same whole-genome sequencing procedures
using an Illumina NovaSeq 6000 sequencing platform and S4
flow cells and subsequently subjected to quality control by
deCODE genetics, as described elsewhere [18].
Defining genomic regions for analysis
All regulatory regions surrounding the index SNP defining the
known, autosomal migraine risk loci [6] were analyzed. We
defined the genomic search regions as 1 Mb pairs upstream
and downstream of the index SNP (see supplementary Table 1
for regions). In the 2 Mb pair window, the genomic positions
(according to the Genome Reference Consortium Human
Build 38 GRCh38.p12 (hg38)) of all regulatory regions were
annotated using BED files downloaded from the UCSC
Table browser [19]. These BED files included insulators [20,
21], polycomb group response elements (PREs) [20, 21], en-
hancers [22], transcription factor binding sites (TFBS) [21],
CpG islands [23], and promoters [24]. All BED files were
downloaded on 02/21/2019 except for the BED file of the
PREs (downloaded on 02/28/2019). Any genomic coordinates
from the hg19 assembly were subsequently converted to the
hg38 assembly. In total, 1079 insulators; 518 PREs; 1651
enhancers; 16,190 TFBSs; 828 CpG islands; and 135 pro-
moters were mapped and subjected to familial association
analysis. Within the regulatory regions, only genetic variants
with a minor allele frequency (MAF) < 5% were assessed.
Familial association analysis
VCF files of each participant in the study were merged,
multiallelic sites were split into a biallelic representation,
the positions of the regulatory regions were annotated, and
rare genetic variants (MAF < 5%) were isolated. The rare-
variant association analysis was carried out with the soft-
ware of Family Sequence Kernel Association Test (F-
SKAT) [25]. Age and gender were used as covariates.
The age was defined as the age at the time of the interview
(the time of diagnosis). The analysis was performed with
all default options in effect, and the resulting p values were
controlled for multiple testing using the Bonferroni meth-
od. A Bonferroni-corrected p value < 0.05 was considered
significant. To assess whether the findings were dependent
on the original index SNP of the migraine GWAS, the
number of alleles of the index SNP (0, 1, or 2) were applied
as additional covariates in a separate rare-variant associa-
tion analysis with F-SKAT.
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Replication
The findings from the familial association analysis were
assessed in a case-control design using an independent cohort
of sporadic migraineurs with no familial history of migraine
and controls. Aggregated data were available on rare variants
(MAF < 5%) in the regulatory regions for the controls. Thus,
we tested whether the frequency of rare variants was increased
in sporadic migraineurs compared to the controls under the
null hypothesis of no association with migraine and under a
dominant model of penetrance, using a χ2 test [26]. The
resulting p values were controlled for multiple testing using
the Bonferroni method. A Bonferroni-corrected p value
< 0.05 was considered significant.
eQTL and gene expression analysis
Regulatory regions with an increased burden of rare variants
were subsequently assessed using gene expression data and
single-tissue cis-eQTL data from the Genotype-Tissue
Expression (GTEx) version 8.0 dataset (dbGaP Accession
phs000424.v8.p2, 2019-08-26 release). All SNP identifiers
were found in the Database of Single Nucleotide
Polymorphisms (dbSNP) [27] build 152.
Results
Increased burden of rare variants found in four
regulatory regions
We analyzed 155 migraine families (n = 1040) and 37 autoso-
mal migraine risk loci (supplementary Table 1) and found a
significant increased burden of rare variants segregating with
migraine in 39 regulatory regions (see supplementary Table 2
for regulatory regions and p values). As expected, when ana-
lyzing rare variants in regions, that are known to harbor poly-
genic effects in the known risk loci [6, 28, 29], we found that
the distribution of the test statistics deviated from the null, with
a genomic inflation factor of λ = 1.89 (supplementary Fig. 1).
In an independent case-control cohort using sporadic
migraineurs with no familial history of migraine (ncases =
2027) and controls (ncontrols = 1650), assuming a dominant
model of penetrance, we verified that four of the regulatory
regions had an increased burden of rare variants (Table 1). The
four regulatory regions include a CpG island located near the
PHACTR1 migraine risk locus and three PREs located near
the KCNK5, ASTN2, and RNF213 migraine risk locus. The
CpG island located near the PHACTR1 migraine risk locus
associated with the highest migraine risk, having an odds ratio
(OR) of 1.54 (Fig. 1). Extensive information of the rare vari-
ants identified for the four regulatory regions is available in
supplementary Table 3.
Association of migraine and rare regulatory variants
independent of known risk loci
Subsequently, we tested whether the four regulatory regions
with increased burden were correlated with the index SNP of
the migraine risk loci. Using the risk allele count of the index
SNP as covariate, we found a nonsignificant effect on the
results defining each migraine risk locus as additional covar-
iates (Table 2).
Possible regulatory targets identified for three
regulatory regions
To shed light on the biological mechanisms regulated by the
regulatory regions, the genic regulatory targets were sought to
be identified. The CpG island near the PHACTR1 migraine
risk locus is overlapping the promoter region of various splice
variants of theGFOD1 gene and the non-codingGFOD1-AS1
gene (Fig. 2a). We also found two cis-eQTLs within the CpG
island that associated with GFOD1 transcript levels
(supplementary Table 4). Analysis of the gene expression in
the GTEx database indicates that GFOD1 is expressed across
different kinds of tissue and is highly expressed in brain and
vascular tissue (Fig. 3a).
PREs can be situated far away from their target genes, in
introns, or in the 3′ untranslated regions (UTRs) [30]. Thus,
Table 1 Results from replication using an independent case-control
cohort of sporadic migraineurs and controls. The table presents the name
andMAF of the index SNP of the migraine risk loci, as given byGormley
et al. (2016) [6], the genomic positions of the regulatory regions, the type
of regulatory regions, the Bonferroni-corrected p values, and the ORs
with the 95% confidence intervals (CI)
Locus MAF Position (chromosome:start:end) Type p value OR (95% CI)
PHACTR1 0.41 chr6:13486092:13488560 CpG island 5.3·10−15 1.54 (1.44–1.65)
KCNK5 0.28 chr6:39310446:39312846 PRE 0.014 1.24 (1.1–1.39)
ASTN2 0.36 chr9:116284900:116285300 PRE 0.017 1.5 (1.18–1.9)
RNF213 0.17 chr17:79742606:79746206 PRE 9.3·10−5 1.12 (1.07–1.18)
Neurogenetics (2020) 21:149–157 151
the relations of the PREs to genes are based on cis-eQTLs in
the GTEx database. Significant cis-eQTLs in the PRE near the
KCNK5 locus mapped to the KCNK17 and KIF6 gene
(supplementary Table 4). The PRE is situated across two in-
trons and one exon of the KCNK17 gene (Fig. 2b). According
to GTEx, KCNK17 is primarily expressed in vascular tissue
(Fig. 3b) whileKIF6 is mainly expressed in the brain (Fig. 3c).
The PRE near the RNF213 locus harbored cis-eQTLs that
associated with the transcript levels of five different genes.
These include the nearby genes of CBX2, LINC0207,
ENPP7, TBC1D16, and CARD14 (Fig. 2c). We do not note
a higher expression of these genes in brain or vascular tissue
compared to other tissue types (Fig. 3d–h).
The PRE situated near the ASTN2 locus is located in an
intron of the PAPPA gene (Fig. 2d). No significant cis-eQTLs
could be found within this PRE.
No increased burden of rare variants in regulatory
targets
We assessed whether the possible gene targets of the four regu-
latory regions had an increased burden of rare variants
segregating with migraine. Using a familial association analysis,
we did not find a significantly increased burden of rare variants
segregating with migraine after Bonferroni correction (Table 3).
The analysis was performed on the protein-coding genes only.
Discussion
Migraine is most often an episodic disorder and can be affected
by regulatory factors, such as hormones. It is therefore very likely
that gene dysregulation plays a causal role in migraine etiology.
Here, we have assessed the hypothesis that an increased burden
of rare regulatory variants in known migraine risk loci can be
associated with a risk of migraine. We also addressed whether
the association is independent of the common risk variants in the
loci. We found four regulatory regions with an OR > 1, in which
an increased burden of rare variants is independently associated
with migraine. We report eight possible regulatory target genes.
These genes are different than those in which the index SNPs of
the known migraine risk loci resides in.
The CpG island near the PHACTR1 locus is overlapping
the promoter region of various splice variants of the GFOD1
gene and the non-codingGFOD1-AS1 gene. As about 70% of
all promoters are located in a CpG island-rich area [31], it is
highly likely that this CpG island is involved in the regulation
of the GFOD1 and the GFOD1-AS1 gene. The regulation of
the GFOD1 gene is supported by the existence of two cis-
eQTLs within the CpG island, that are associated with
GFOD1 transcript levels. Interestingly, the research group of
Lasky-Su et al. [32] has reported a SNP in an intron of the
GFOD1 gene that associated with ADHD, which is a comor-
bid disorder of migraine [33, 34]. Thus, the findings of this
study could help elucidate the association between the disor-
ders. Analysis of the gene expression in the GTEx database
indicates thatGFOD1 is expressed predominantly in brain and
vascular tissue, which are tissue types that have been connect-
ed with migraine [35, 36]. Transcription of antisense non-
Fig. 1 Effect of regulatory
regions on migraine risk. The
figure presents the effect of the
significant regulatory regions on
migraine risk. X-axis: OR (dot)
with the 95% confidence intervals
(lines). Y-axis: The genomic po-
sitions (given as
chromosome:start:end) and type
of regulatory regions and the mi-
graine risk loci in brackets
Table 2 Results obtained with familial association analysis using the
presence of the index SNP as additional covariates. The table gives the
name of the migraine risk loci, the type of regulatory regions, and the
Bonferroni-corrected p values with and without applying the presence of
the index SNP as additional covariates
Locus Type p value without allele
count of index SNP
as covariate
p value with allele
count of index SNP
as covariate
PHACTR1 CpG island 0.044 0.042
KCNK5 PRE 0.011 0.012
ASTN2 PRE 0.011 0.011
RNF213 PRE 5.7·10−3 5.8·10−3
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Fig. 2 The genomic regions in which the four regulatory regions are
located. In the top of each figure is 1 Mb pairs upstream and
downstream of the index SNP defining the migraine risk loci displayed.
Within this 2Mb pair window, regulatory regions were annotated and rare
variants within these were assessed. The index SNP defining the migraine
risk loci is located in the middle, and below are the regulatory regions (the
CpG island and the PREs) in which rare variants associated with an
increased migraine risk and genic transcript information. In the bottom
of each figure is a close-up of the regulatory regions. Here, the rare
variants, that had an increased burden in the familial association analysis,
are indicated. The genomic regions surrounding a the PHACTR1 locus
and the CpG island, b theKCNK5 locus and the PRE, c theRNF213 locus
and the PRE, and d the ASTN2 locus and the PRE
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coding RNAs has been shown to participate in both cis and
trans gene regulation [37], and it is thus possible thatGFOD1-
AS1 plays an important regulatory role on GFOD1.
Variations within CpG islands have been shown to influ-
ence DNAmethylation patterns. Depending on the increase or
elimination of CpG dinucleotides, the mutations may lead to
hyper- or hypomethylation and, therefore, an altered transcrip-
tional activity [38]. If CpG islands are hypermethylated, they
may cause a stable silencing of the gene. In contrast, a hypo-
methylation can result in an overexpression [39]. Therefore,
such changes of the CpG sites with the CpG island could
affect the expression of GFOD1.
Significant cis-eQTLs in the PREnear theKCNK5 locus drive
a change in the gene expression of KCNK17 and KIF6. The
KCNK17 gene encodes a membrane protein and belongs to the
family of two-pore domain potassium (K2P) channels. Of the
same K2P channel subfamily is the protein product of the
KCNK5 gene [40], in which the index SNP defining themigraine
risk locus resides. From a different subfamily is the KCNK18
gene where a frameshift mutation has been found to segregate
perfectly in families with migraine with aura [41]. Additionally,
previously identified migraine-associated genes include genes
encoding potassium channels [41, 42]. Cortical spreading depres-
sion has been associated with migraine attacks [4], and because
cortical spreading depression is characterized by ion influxes and
neuronal depolarization, genetic alterations affecting potassium
channels could play a role in this. The findings of our study could
support that migraine may be a channelopathy and that potassi-
um ion channels influence the disorder.
The PRE near the RNF213 locus harbored cis-eQTLs that
act upon five different genes. These include the nearby genes
of CBX2, LINC0207, ENPP7, TBC1D16, and CARD14. The
protein encoded by the CARD14 gene mediates the activation
of transcription factor NF-κB [43]. NF-κB plays a part in
induction of nitric oxide production [44], which has been im-
plied as having a key causative role in migraine [45] and can
induce headache in healthy subjects [46]. Therefore, inhibi-
tion of NF-κB has been proposed as a possible therapeutic
approach to treat migraine [47].
PREs are a class of silencers that have a suppressive effect
on gene expression, when polycomb group (PcG) proteins are
Fig. 3 Expression of the possible genic regulatory targets across different
tissues. The figure displays expression data from the GTEx database
where the tissue types have been divided according to tissue group
(brain, vascular, and other remaining tissue). Y-axis: the expression in
transcripts per million (TPM). Expression of a GFOD1, b KCNK17, c
KIF6, d CBX2, e LINC02078, f ENPP7, g TBC1D16, h CARD14
Table 3 Results from familial association analysis on rare variants
segregating with migraine in the possible genic regulatory targets. The
name of the migraine risk loci, the regulatory regions, and the
corresponding possible genic regulatory target are presented.
Additionally, the nominal p value and the Bonferroni-corrected p value
of the familial association analysis are displayed
Locus Type Gene target Nominal p value Corrected
p-value
PHACTR1 CpG island GFOD1 0.088 0.62
KCNK5 PRE KCNK17 7.6e-3 0.053
KIF6 0.014 0.098
RNF213 PRE CBX2 0.049 0.34
ENPP7 0.056 0.39
TBC1D16 0.037 0.26
CARD14 0.098 0.69
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bound to them. Mutations within a PRE could result in re-
duced silencer activity and therefore lead to an increased gene
expression. If mutations within the PRE results in increased
expression of CARD14, it could therefore cause an increased
activation of NF-κB and thus influence migraine.
The CBX2 gene encodes a subunit of the PRC1-like com-
plex, which is a PcG protein. Thus, this PcG protein partici-
pates in suppression of gene expression through binding to
PREs. Thus, if the expression of the CBX2 gene is altered, it
could result in altered gene regulation.
Aside from finding a connection between a PcG protein
and migraine, we have also found associations between an
increased burden of rare variants in three PREs and migraine.
It is interesting, that we find multiple connections between an
increased migraine risk and PREs and proteins that bind to
them. In humans, PREs are known to be influential on human
embryonic development and epigenetic memory [48] but the
function and regulatory mechanism of action of mammalian
PREs is still largely unknown [49]. It is therefore speculative,
what effect PREs have on migraine. As more knowledge on
PREs is gained in the future, we may be able to understand
how their altered regulatory mechanism may affect migraine.
PcG proteins have been suggested to act synergistically in
order to silence gene expression [50]. Consequently, any mu-
tated PcG binding site within a PRE may cause an altered
phenotype. Future research could include determining if the
PREs we find associated with migraine harbor PcG bindings
sites that have been altered by the rare mutations.
Lastly, we addressed whether only the regulatory regions
had a higher burden of rare variants segregating with migraine
or if the genes possibly targeted by the regulatory regions had a
higher burden of rare variants. We found that none of the
protein-coding possible genic regulatory targets had a signifi-
cantly increased burden of rare variants segregating with mi-
graine. This suggests that a higher burden of rare variants in the
regulatory regions, and not their respective regulatory targets, is
implicated in the pathophysiology of migraine. This supports
that migraine is influenced by gene dysregulation and that reg-
ulatory dysfunction has a crucial impact on the disorder.
Conclusion
We report that families with familial clustering of migraine
have an increased burden of rare variants segregating with
migraine in regulatory regions. The regulatory regions are
located near known migraine risk loci but display effects in-
dependent of the common variants defining the loci. The pos-
sible regulatory targets suggest different genes than those orig-
inally tagged by the index SNPs of the migraine loci. The
findings support that gene dysregulation plays a crucial, if
not causal, role in migraine etiology.
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